Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at the Society for...

Novartis announced today results from the FUTURE 5 study showing Cosentyx® (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression...

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product...

Nektar Therapeutics (Nasdaq: NKTR) today announced it is presenting preclinical data on NKTR-358, a potential first-in-class resolution therapeutic that may address the underlying immune system...

Pique Therapeutics, Inc. today announced positive results for PT 107 from its Phase 2 clinical trial in patients with late-stage, second-line non-small cell lung cancer (NSCLC). These results will...

Elastifile, the enterprise hybrid cloud data management company, today announced that it will be exhibiting its Cross-Cloud Data Fabric at SC17, the international conference for high performance...

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today...

Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, will be participating in...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the...

Asembia is pleased to announce Sylvester Stallone will headline the 2018 general session at the company's annual Specialty Pharmacy Summit. Stallone has established worldwide recognition as an...